{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:23:53Z","timestamp":1767828233691,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1093\/jac\/dkn394","type":"journal-article","created":{"date-parts":[[2008,9,24]],"date-time":"2008-09-24T00:45:12Z","timestamp":1222217112000},"page":"1392-1400","source":"Crossref","is-referenced-by-count":18,"title":["Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC\u00ae: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry"],"prefix":"10.1093","volume":"62","author":[{"given":"David L.","family":"Paterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirando","family":"Mrsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Cetkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Hua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Sterba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregerly","family":"Krivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darinka","family":"Boskovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minqiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,9,23]]},"reference":[{"key":"key\n\t\t\t\t20170425171043_DKN394C1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0025-6196(12)60281-X","article-title":"Antifungal agents used for deep-seated mycotic infections","volume":"67","author":"Terrell","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170425171043_DKN394C2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/313748","article-title":"Introduction to antifungal drugs","volume":"30","author":"Dismukes","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4065\/73.12.1205","article-title":"Antifungal agents. Part I. Amphotericin B preparations and flucytosine","volume":"73","author":"Patel","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20170425171043_DKN394C5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425171043_DKN394C6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity","volume":"43","author":"Luber","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425171043_DKN394C7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated withy amphotericin B for suspected or proven aspergillosis","volume":"27","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00007890-198303000-00005","article-title":"Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation","volume":"35","author":"Kennedy","year":"1983","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20170425171043_DKN394C9","article-title":"AMPHOTEC package insert"},{"key":"key\n\t\t\t\t20170425171043_DKN394C10","article-title":"ABELCET package insert"},{"key":"key\n\t\t\t\t20170425171043_DKN394C11","article-title":"AMBISOME package insert"},{"key":"key\n\t\t\t\t20170425171043_DKN394C12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t20170425171043_DKN394C13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170425171043_DKN394C14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/infdis\/173.5.1208","article-title":"Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant","volume":"173","author":"Bowden","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF01575124","article-title":"Safety of amphotericin B colloidal dispersion","volume":"16","author":"Herbrecht","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","article-title":"The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses","volume":"21","author":"Oppenheim","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.42.3.606","article-title":"Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion","volume":"42","author":"Anaissie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425171043_DKN394C18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/clinids\/20.4.755","article-title":"Pretreatment regimens for adverse events related to infusion of amphotericin B","volume":"20","author":"Goodwin","year":"1995","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects","volume":"277","author":"World Medical Association","year":"1997","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170425171043_DKN394C22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170425171043_DKN394C23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170425171043_DKN394C24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170425171043_DKN394C25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425171043_DKN394C26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N EnglJ Med"},{"key":"key\n\t\t\t\t20170425171043_DKN394C27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0272-6386(98)70046-0","article-title":"Renal effects of amphotericin B lipid complex","volume":"31","author":"Luke","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C29","article-title":"Abelcet (amphotericin B lipid complex) vs amphotericin B for treatment of invasive candidiasis: a prospective, randomised multicenter trial","volume-title":"Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995","author":"Anaissie"},{"key":"key\n\t\t\t\t20170425171043_DKN394C30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/j.1875-9114.1990.tb02593.x","article-title":"Prospective surveillance of intravenous amphotericin B use patterns","volume":"10","author":"Grasela","year":"1990","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170425171043_DKN394C32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1445-5994.2004.00695.x","article-title":"Reply","volume":"34","author":"Slavin","year":"2004","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20170425171043_DKN394C34","first-page":"3","article-title":"Invasive fungal infections in immunocompromised patients: a review of antifungal agents","volume":"1","author":"Bierman","year":"2006","journal-title":"US Pharm"},{"key":"key\n\t\t\t\t20170425171043_DKN394C35","first-page":"192","article-title":"Management of invasive fungal infections in oncological patients","volume":"22","author":"Hebarta","year":"1999","journal-title":"Onkologie"},{"key":"key\n\t\t\t\t20170425171043_DKN394C36","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170425171043_DKN394C37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705113","article-title":"Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation","volume":"36","author":"Dvorak","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170425171043_DKN394C38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/500934","article-title":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers","volume":"42","author":"Cordonnier","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425171043_DKN394C39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa071366","article-title":"Hydrocortisone therapy for patients with septic shock","volume":"358","author":"Sprung","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425171043_DKN394C40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1444-0903.2004.00541.x","article-title":"Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections","volume":"34","author":"Slavin","year":"2004","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20170425171043_DKN394C41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1406.019","article-title":"Amphotericin B and coccidioidomycosis","volume":"1111","author":"Johnson","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"key\n\t\t\t\t20170425171043_DKN394C42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2710.1999.00220.x","article-title":"A comparative review of conventional and lipid formulations of amphotericin B","volume":"24","author":"Robinson","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t20170425171043_DKN394C43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/516321","article-title":"Amphotericin B use in a community hospital, with special emphasis on side effects","volume":"26","author":"Pathak","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/62\/6\/1392\/13759228\/dkn394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:38:41Z","timestamp":1709246321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkn394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,23]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,9,23]]},"published-print":{"date-parts":[[2008,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkn394","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9,23]]}}}